OF
Omega Funds
Venture CapitalActiveOmega Funds global life sciences-based investment firm specialized in direct secondary transactions.
71
Investments
9
Exits
$1.2B
AUM
12.7%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for Omega Funds.
Investment Thesis & Strategy
Omega Funds invests in various stages of biotech and healthcare companies, with a focus on direct secondary transactions.
Investment Activity
Deals per year over the last 14 years
1
20080
20091
20100
20111
20120
20131
20142
20152
20161
20171
20180
20191
20201
2021Portfolio Companies
Selected investments from their portfolio of 71 companies
C
Cerevel Therapeutics
Biotech · Growth, 2021
O
Obsidian Therapeutics
Biotech · Series B, 2020
G
Gyroscope Therapeutics
Biotech · Series B, 2018
A
Alector
Biotech · Series B, 2017
O
ObsEva
Biotech · Series B, 2016
K
Kodiak Sciences
Biotech · Series A, 2016
A
Arvinas
Biotech · Series B, 2015
V
Voyager Therapeutics
Biotech · Series A, 2015
B
Biohaven Pharmaceutical
Biotech · Series A, 2014
A
Apellis Pharmaceuticals
Biotech · Series A, 2012
A
Affimed
Biotech · Series A, 2010
E
Esperion Therapeutics
Biotech · Series A, 2008
Notable Exits
CompanyTypeYearValue / Acquirer
ObsEvaAcquisition2023—
Esperion TherapeuticsIPO2019—
Portola PharmaceuticalsAcquisition2019$1.4B
SequenomAcquisition2016—
ReceptosAcquisition2015$7.2B
PharmacyclicsAcquisition2015$21B
Ambit BiosciencesAcquisition2014$410M
Neurocrine BiosciencesIPO2014—
Aragon PharmaceuticalsAcquisition2013$430M
Frequently Asked Questions
Omega Funds focuses on Series A, Series B, Series C+ stage investments.